-
DYNE-251 leads to improvements in motor function in DMD: Update
Up to a year of treatment with DYNE-251, Dyne Therapeutics’ investigational exon 51-skipping therapy, led […]
-
Raising Our Voices for Duchenne: Recap of PPMD’s Advocacy Webinar
On Thursday, September 5, 2024, PPMD hosted a special webinar, “PPMD Advocacy: Raising Our Voices […]
-
Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program
SEE THE FULL PRESS RELEASE BELOW AND HERE – Second annual DREAMS Grant Program awards […]
-
Myology Course Educates and Advances Next Generation of Neuromuscular Physicians and Scientists
PPMD is dedicated to fighting for every future as we strive to end Duchenne. Since […]
-
CureDuchenne Submits Comments on FDA’s Draft Guidance for Industry on Platform Technology Designation Program
CureDuchenne welcomes the recent initiative the Food and Drug Administration (FDA) has taken to improve […]
-
Noninvasive qMRI seen to detect muscle changes in LGMD type R1
A noninvasive quantitative MRI, or qMRI, was found to detect early muscle abnormalities among people […]
-
Introducing PPMD’s Newborn Screening Action Center: A Hub for Advocacy and Education
We are thrilled to announce the launch of PPMD’s Newborn Screening Action Center, a powerful […]
-
Dyne Therapeutics Announces Positive New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne
Dyne Therapeutics, Inc. has announced positive new clinical data from its ongoing Phase 1/2 DELIVER […]
-
Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts
As an early investor in Dyne Therapeutics, CureDuchenne is pleased share that Dyne announced positive […]
-
Raising Our Voices This Duchenne Action Month
PPMD is excited to join forces with fellow Duchenne-specific organizations from around the world to […]
